RE-Stem Biotech is a biotechnology firm engaged in the research and development of cell therapies targeting osteoarthritis, spinal cord injury and various cancers.
RE-Stem specializes in clinically translatable cell therapies (stem cell & immune cells), stem cell-derived products, and cell banking, as well as supplying stem cells to other enterprises.
RE-Stem has been built by an international team of seasoned scientists and expert executives.
Error: Contact form not found.
RE-Stem Biotech is a biotechnology firm engaged in the research and development of cell therapies targeting osteoarthritis, spinal cord injury and various cancers. Backed by state-of-the-art GMP facilities and an international team of world-leading scientists, doctors and directors, RE-Stem currently has a robust technology platform including three profitable therapies on the market and six additional therapies.
FIND OUT MORE
RE-Stem specializes in clinically translatable cell therapies (stem cell & immune cells), stem cell-derived products, and cell banking, as well as supplying stem cells to other enterprises.
RE-EnableTM is a proprietary cell-based intervention which, coupled with surgical procedure Re-HabTM, provides a unique survival / regenerative opportunity that has shown remarkable functional recovery.
RE-AGN 2.0 is a proprietary immuno-oncology therapy being developed to address lung and liver cancers.
RE-KneewTM is an autologous human adipose-derived mesenchymal stem cell (haMPC) therapy developed to address knee osteoarthritis.
Suzhou, Jiangsu, CHINA
Time zone (GMT+8)